Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Consumer Staples Select Sector SPDR Fund — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Consumer Staples Select Sector SPDR Fund trades at $86.39 (market cap $14.15B). The key difference: Consumer Staples Select Sector SPDR Fund is the larger of the two by market cap, and Consumer Staples Select Sector SPDR Fund is more actively traded (10,004,762 versus 1,441,031). Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Consumer Staples Select Sector SPDR Fund for 73 Days on average.
| SYRE | XLP | |
|---|---|---|
Market Cap | $7.52B | $14.15B |
Volume | 1,441,031 | 10,004,762 |
Sector | Health | — |
52-Week High | $108.92 | $90.00 |
52-Week Low | $22.18 | $75.61 |
Typical Hold Time | 0 Days | 73 Days |
Enterprise Value | $6.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
XLP trades at $84.19, down 0.26% on the day, with a bullish technical outlook supported by moving averages and ADX signals. Analyst consensus is unanimously positive with 100% buy ratings. Recent news highlights its competitive expense ratio and defensive appeal amid market volatility, with strong performance relative to discretionary sectors in 2026.
The ETF's low costs and sector resilience underpin a favorable outlook, though overbought RSI levels and interest rate sensitivity pose near-term risks. Institutional favor and dividend stability offer long-term value, but macroeconomic pressures require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
